Antidepressant-like effect of Ganoderma lucidum spore polysaccharide-peptide mediated by upregulation of prefrontal cortex brain-derived neurotrophic factor

Zhao, Shuang; Rong, Chengbo; Gao, Yi; Wu, Liangliang; Luo, Xiaoheng; Song, Shuang; Liu, Yu; Wong, Jack Ho; Wang, Hexiang; Yi, Long; Ng, T.B.

doi:10.1007/s00253-021-11634-y

Cited by 14 publications

(15 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fourteen of the studies used rats ( Matsuzaki et al, 2013 ; Minami et al, 2013 ; Tan et al, 2016 ; Liu C. et al, 2017 ; Song et al, 2017 ; Wang et al, 2017 ; Huang et al, 2020 ; Nascimento et al, 2020 ; Lin et al, 2021a ; Zhang L. et al, 2021 ; Lin et al, 2021b ; Anuar et al, 2022 ; Cheng, 2023 ; Rakoczy et al, 2023 ), while the remaining 36 studies used mice to test for antidepressant-like effects ( Zhou et al, 2005 ; Nishizawa et al, 2007 ; Koo et al, 2008 ; Singh et al, 2014 ; Tianzhu et al, 2014 ; Socala et al, 2015 ; Yao et al, 2015 ; Gupta et al, 2016 ; Huang et al, 2016 ; Nakamichi et al, 2016 ; Song et al, 2016 ; Xu, 2016 ; Bao et al, 2017 ; Liu Y. et al, 2017 ; Lin et al, 2017 ; Chiu et al, 2018 ; Mahmoudi et al, 2018 ; Ryu et al, 2018 ; Jin et al, 2019 ; Li et al, 2019 ; Song et al, 2020 ; Li H. et al, 2021 ; Li TJ. et al, 2021 ; Zhang T. et al, 2021 ; Chong et al, 2021 ; Hossen et al, 2021 ; Park et al, 2021 ; Singh et al, 2021 ; Zhao et al, 2021 ; Chou et al, 2022 ; Mi et al, 2022 ; Xin et al, 2022 ; Yu et al, 2022 ; Ezurike et al, 2023 ; Zhao et al, 2023 ; Hernandez-Leon et al, 2024 ). In terms of strains, 10 of the rat studies used Sprague-Dawley, three included Wistar and one used Long-Evans rats.…”

Section: Resultsmentioning

confidence: 99%

A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity

Wang,

Kim,

Aleksandrova

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

One of the most important developments in psychopharmacology in the past decade has been the emergence of novel treatments for mood disorders, such as psilocybin for treatment-resistant depression. Psilocybin is most commonly found in different species of mushroom; however, the literature on mushroom and fungus extracts with potential antidepressant activity extends well beyond just psilocybin-containing mushrooms, and includes both psychedelic and non-psychedelic species. In the current review, we systematically review the preclinical literature on mushroom and fungus extracts, and their effects of animal models of depression and tests of antidepressant activity. The PICO structure, PRISMA checklist and the Cochrane Handbook for systematic reviews of intervention were used to guide the search strategy. A scoping search was conducted in electronic databases PubMed, CINAHL, Embase and Web of Science. The literature search identified 50 relevant and suitable published studies. These included 19 different species of mushrooms, as well as seven different species of other fungi. Nearly all studies reported antidepressant-like effects of treatment with extracts. Treatments were most commonly delivered orally, in both acute and chronically administered studies to predominantly male rodents. Multiple animal models of depression were used, the most common being unpredictable chronic mild stress, while the tail suspension test and forced swim test were most frequently used as standalone antidepressant screens. Details on each experiment with mushroom and fungus species are discussed in detail, while an evaluation is provided of the strengths and weaknesses of these studies.

show abstract

Section: Resultsmentioning

confidence: 99%

A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity

Wang,

Kim,

Aleksandrova

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…BDNF has become a representative factor in depression research. The blood of patients with persistent and recurrent depression, as well as animal models of depression, have been consistently found to exhibit reduced levels of NTF in numerous studies ( Zhao et al, 2021 ; Zhuang et al, 2022 ; Joo et al, 2023 ). The conventional and rapid antidepressants not only rely on the expression of BDNF and its downstream signaling for their efficacy, but they also directly interact with the transmembrane structural domain of the TrkB dimer, leading to the stabilization of a multiprotein complex conformation that facilitates TrkB binding to BDNF.…”

Section: Antidepressant Mechanism Of Natural Plant Polysaccharidesmentioning

confidence: 99%

A review of the pharmacological action and mechanism of natural plant polysaccharides in depression

Yang,

Li,

Zhang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Depression is a prevalent mental disorder. However, clinical treatment options primarily based on chemical drugs have demonstrated varying degrees of adverse reactions and drug resistance, including somnolence, nausea, and cognitive impairment. Therefore, the development of novel antidepressant medications that effectively reduce suffering and side effects has become a prominent area of research. Polysaccharides are bioactive compounds extracted from natural plants that possess diverse pharmacological activities and medicinal values. It has been discovered that polysaccharides can effectively mitigate depression symptoms. This paper provides an overview of the pharmacological action and mechanisms, intervention approaches, and experimental models regarding the antidepressant effects of polysaccharides derived from various natural sources. Additionally, we summarize the roles and potential mechanisms through which these polysaccharides prevent depression by regulating neurotransmitters, HPA axis, neurotrophic factors, neuroinflammation, oxidative stress, tryptophan metabolism, and gut microbiota. Natural plant polysaccharides hold promise as adjunctive antidepressants for prevention, reduction, and treatment of depression by exerting their therapeutic effects through multiple pathways and targets. Therefore, this review aims to provide scientific evidence for developing polysaccharide resources as effective antidepressant drugs.

show abstract

“…PGL reversed depression behaviors in mice after acute and chronic administration. The administration of isolated PGL resulted in upregulation of BDNF/TrkB expression in the prefrontal cortex [ 146 ].…”

Section: Medicinal Mushrooms and Their Impact On Neurotrophins—neurot...mentioning

confidence: 99%

“…The 28 kDa polysaccharide peptide isolated from Ganoderma lucidum spores showed antidepressant activity in mouse model of depression induced by unpredictable chronic mild stress. The antidepressant mechanism of action was the upregulation of BDNF in the PFC [ 146 ].…”

Section: Medicinal Mushrooms and Their Impact On Neurotrophins—neurot...mentioning

confidence: 99%

Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review

et al. 2023

View full text Add to dashboard Cite

Major Depression Disease is a common mental illness that affects more than 322 million people worldwide and it is one of the leading causes of mental and physical disability. The etiology of depression is a complex interplay of psychological, social, and biological factors. Currently, psychopharmacotherapy is based mainly on the monoamine theory, which states that depression is caused by an insufficient level of monoamines such as serotonin, norepinephrine, and/or dopamine. Due to the relatively low efficacy of the typical antidepressant and the high prevalence of treatment-resistant depression (~30%), seeking new ways of prophylaxis, adjuvant therapy, or novel compounds with antidepressant activity, is a priority. According to studies that analyzed mushroom consumption patterns and depression prevalence, it was concluded that mushroom ingestion lowers the odds of depression. Medicinal mushrooms are considered functional foods because of their ability to synthesize and accumulate different types of metabolites, which enhance their health-promoting properties. The review aims to explain the antidepressant activity of edible/medicinal mushrooms by elucidating the mechanism from different perspectives: edible mushrooms as a source of serotonin precursors and psilocybin as a rapid-acting antidepressant. These compounds exhibit anti-neuroinflammatory and antioxidant activities that impact neurotrophin expression, the neurogenesis process, and influence on the gut–brain axis.

show abstract

Antidepressant-like effect of Ganoderma lucidum spore polysaccharide-peptide mediated by upregulation of prefrontal cortex brain-derived neurotrophic factor

Cited by 14 publications

References 69 publications

A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity

A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity

A review of the pharmacological action and mechanism of natural plant polysaccharides in depression

Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review

Contact Info

Product

Resources

About